Recent Company News

• 04:17 AM ET Oct 21, 2025
  

  Chugai Pharmaceutical reports Alecensa median overall survival of 81.1 months in ALK-positive non-small cell lung cancer (¥7158.0000, 0)

• 07:33 AM ET Oct 17, 2025
  

  Rani Therapeutics announces up to $1.085B collaboration with Chugai Pharmaceutical, concurrent oversubscribed $60.3M financing ($0.47, 0.00)

• 08:10 AM ET Oct 15, 2025
  

  Chugai Pharmaceutical notes Eli Lilly reports topline results from phase 3 ACHIEVE-2 and ACHIEVE-5 trials of orforglipron (¥7025.0000, 0)

• 07:01 PM ET Oct 14, 2025
  

  Eli Lilly to launch new obesity drug Retatrutide for patients with severe cases as soon as 2027 - Nikkei ($812.35, 0.00)

• 10:51 PM ET Oct 13, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 04:09 AM ET Oct 10, 2025
  

  Roche gives Chugai Pharmaceutical exclusive rights to develop and market CT-388 in Japan (¥7479.0000, 0)

• 02:23 AM ET Oct 03, 2025
  

  FDA approves PharmaMar's Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) Combination as First-line Maintenance Therapy for Extensive-stage Small Cell Lung Cancer. (€93.00, 0.00)

• 03:23 PM ET Oct 02, 2025
  

  FDA approves Jazz Pharmaceuticals' Zepzelca (lurbinectedin) in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for ES-SCLC whose disease has not progressed ($137.56, +0.66)

• 12:50 PM ET Sep 26, 2025
  

  White House says the latest pharmaceutical tariffs do not apply to countries with negotiated trade deals -- wires

• 08:15 PM ET Sep 25, 2025
  

  Trump says pharmaceutical products imported into US will be hit with 100% tariff starting 1-Oct - Truth Social post